US Penny Stocks To Consider In December 2024

In This Article:

As the United States stock market navigates a period of volatility, with major indexes managing to hold onto gains despite recent fluctuations, investors are exploring diverse opportunities. Penny stocks, though often viewed as a throwback term, continue to offer potential for growth by representing smaller or newer companies at lower price points. When these stocks are backed by strong financials and solid fundamentals, they can provide an intriguing opportunity for investors seeking hidden value in the market.

Top 10 Penny Stocks In The United States

Name

Share Price

Market Cap

Financial Health Rating

Inter & Co (NasdaqGS:INTR)

$4.25

$1.87B

★★★★☆☆

QuantaSing Group (NasdaqGM:QSG)

$3.08

$104.78M

★★★★★★

BAB (OTCPK:BABB)

$0.86

$6.25M

★★★★★★

Pangaea Logistics Solutions (NasdaqCM:PANL)

$4.89

$229.35M

★★★★★☆

ZTEST Electronics (OTCPK:ZTST.F)

$0.25

$9.2M

★★★★★★

Imperial Petroleum (NasdaqCM:IMPP)

$2.90

$87.96M

★★★★★★

Golden Growers Cooperative (OTCPK:GGRO.U)

$4.50

$67.38M

★★★★★★

BTCS (NasdaqCM:BTCS)

$2.54

$44.07M

★★★★★★

Smith Micro Software (NasdaqCM:SMSI)

$1.45

$25.72M

★★★★★☆

CBAK Energy Technology (NasdaqCM:CBAT)

$1.07

$96.23M

★★★★★☆

Click here to see the full list of 731 stocks from our US Penny Stocks screener.

Let's dive into some prime choices out of the screener.

Atai Life Sciences

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Atai Life Sciences N.V. is a clinical-stage biopharmaceutical company focused on developing and investing in therapeutics for mental health disorders such as depression, anxiety, and addiction, with a market cap of approximately $214.79 million.

Operations: The company's revenue is primarily generated from its business of identifying and advancing mental health innovations, amounting to $0.33 million.

Market Cap: $214.79M

Atai Life Sciences, with a market cap of US$214.79 million, is a pre-revenue biopharmaceutical company focused on mental health therapeutics. Despite its innovative focus, Atai faces financial challenges; it reported significant net losses in recent quarters and was removed from the NASDAQ Biotechnology Index. The company has more cash than debt and sufficient short-term assets to cover liabilities but lacks profitability and experienced management, with an average tenure of 1.2 years. While revenue growth is forecasted at 82.34% annually, achieving profitability remains uncertain over the next three years amidst high share price volatility.